FDA Determines Regulatory Review Period for ALTIUS Direct Electrical Nerve Stimulation System

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for ALTIUS Direct Electrical Nerve Stimulation System, a medical device, following a patent extension application submitted to the US Patent and Trademark Office (USPTO).